Dronedarone for atrial fibrillation: a new therapeutic agent.
Atrial fibrillation is the most common of the serious cardiac rhythm disturbances and is responsible for substantial morbidity and mortality. Amiodarone is currently one of the most widely used and most effective antiarrhythmic agents for atrial fibrillation. But during chronic usage amiodarone can cause some serious extra cardiac adverse effects, including effects on the thyroid. Dronedarone is a newer therapeutic agent with a structural resemblance to amiodarone, with two molecular changes, and with a better side effect profile. Dronedarone is a multichannel blocker and, like amiodarone, possesses both a rhythm and a rate control property in atrial fibrillation. The US Food and Drug Administration approved dronedarone for atrial fibrillation on July 2, 2009. In this review, we discuss the role of dronedarone in atrial fibrillation.
Patel
Pawan D
PD
Department of Cardiology, Chicago Medical School, Chicago, IL 60064, USA.
Bhuriya
Rohit
R
Patel
Dipal D
DD
Arora
Bhaskar L
BL
Singh
Param P
PP
Arora
Rohit R
RR
D000638:Amiodarone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D000077764:Dronedarone; D019317:Evidence-Based Medicine; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D000077764:Dronedarone; D000638:Amiodarone
Am Heart J. 2008 Sep;156(3):527.e1-9
18760136
N Engl J Med. 2008 Jun 19;358(25):2678-87
18565860
J Cardiovasc Pharmacol. 2003 Feb;41(2):191-202
12548079
Br J Clin Pharmacol. 2007 Dec;64(6):785-91
17662087
N Engl J Med. 2007 Sep 6;357(10):987-99
17804843
J Cardiovasc Pharmacol. 2000 Dec;36(6):802-5
11117382
Eur Heart J. 2003 Aug;24(16):1481-7
12919771
J Cardiovasc Pharmacol. 2000 Sep;36(3):376-83
10975596
N Engl J Med. 2005 May 5;352(18):1861-72
15872201
Endocrinology. 2003 Feb;144(2):552-8
12538616
Ann Intern Med. 1994 Oct 1;121(7):529-35
8067651
Clin Endocrinol (Oxf). 2009 Jan;70(1):2-13
18727707
N Engl J Med. 2009 Feb 12;360(7):668-78
19213680
Br J Pharmacol. 2001 Jul;133(5):625-34
11429385
J Cardiovasc Pharmacol. 1995 Sep;26(3):453-61
8583788
Eur J Pharmacol. 1995 Jun 6;279(1):25-32
7556379
Circulation. 1999 Nov 30;100(22):2276-81
10578003
JAMA. 2001 May 9;285(18):2370-5
11343485
J Cardiovasc Pharmacol. 1995 Oct;26(4):570-6
8569217
J Cardiovasc Electrophysiol. 2003 Aug;14(8):885-90
12890054
N Engl J Med. 2009 Apr 30;360(18):1811-3
19403901